S&P 500   3,951.57 (+0.89%)
DOW   32,244.58 (+1.20%)
QQQ   305.97 (+0.35%)
AAPL   157.40 (+1.55%)
MSFT   272.23 (-2.58%)
META   197.81 (+1.12%)
GOOGL   101.22 (-0.39%)
AMZN   97.71 (-1.25%)
TSLA   183.25 (+1.73%)
NVDA   259.00 (+0.68%)
NIO   8.75 (+5.93%)
BABA   81.00 (-0.82%)
AMD   96.81 (-1.05%)
T   18.49 (+1.99%)
F   11.18 (-1.06%)
MU   57.64 (+1.73%)
CGC   1.86 (-7.00%)
GE   89.92 (-0.41%)
DIS   94.22 (+1.09%)
AMC   4.27 (+2.15%)
PFE   40.81 (+1.77%)
PYPL   73.21 (+0.30%)
NFLX   305.13 (+0.54%)
S&P 500   3,951.57 (+0.89%)
DOW   32,244.58 (+1.20%)
QQQ   305.97 (+0.35%)
AAPL   157.40 (+1.55%)
MSFT   272.23 (-2.58%)
META   197.81 (+1.12%)
GOOGL   101.22 (-0.39%)
AMZN   97.71 (-1.25%)
TSLA   183.25 (+1.73%)
NVDA   259.00 (+0.68%)
NIO   8.75 (+5.93%)
BABA   81.00 (-0.82%)
AMD   96.81 (-1.05%)
T   18.49 (+1.99%)
F   11.18 (-1.06%)
MU   57.64 (+1.73%)
CGC   1.86 (-7.00%)
GE   89.92 (-0.41%)
DIS   94.22 (+1.09%)
AMC   4.27 (+2.15%)
PFE   40.81 (+1.77%)
PYPL   73.21 (+0.30%)
NFLX   305.13 (+0.54%)
S&P 500   3,951.57 (+0.89%)
DOW   32,244.58 (+1.20%)
QQQ   305.97 (+0.35%)
AAPL   157.40 (+1.55%)
MSFT   272.23 (-2.58%)
META   197.81 (+1.12%)
GOOGL   101.22 (-0.39%)
AMZN   97.71 (-1.25%)
TSLA   183.25 (+1.73%)
NVDA   259.00 (+0.68%)
NIO   8.75 (+5.93%)
BABA   81.00 (-0.82%)
AMD   96.81 (-1.05%)
T   18.49 (+1.99%)
F   11.18 (-1.06%)
MU   57.64 (+1.73%)
CGC   1.86 (-7.00%)
GE   89.92 (-0.41%)
DIS   94.22 (+1.09%)
AMC   4.27 (+2.15%)
PFE   40.81 (+1.77%)
PYPL   73.21 (+0.30%)
NFLX   305.13 (+0.54%)
S&P 500   3,951.57 (+0.89%)
DOW   32,244.58 (+1.20%)
QQQ   305.97 (+0.35%)
AAPL   157.40 (+1.55%)
MSFT   272.23 (-2.58%)
META   197.81 (+1.12%)
GOOGL   101.22 (-0.39%)
AMZN   97.71 (-1.25%)
TSLA   183.25 (+1.73%)
NVDA   259.00 (+0.68%)
NIO   8.75 (+5.93%)
BABA   81.00 (-0.82%)
AMD   96.81 (-1.05%)
T   18.49 (+1.99%)
F   11.18 (-1.06%)
MU   57.64 (+1.73%)
CGC   1.86 (-7.00%)
GE   89.92 (-0.41%)
DIS   94.22 (+1.09%)
AMC   4.27 (+2.15%)
PFE   40.81 (+1.77%)
PYPL   73.21 (+0.30%)
NFLX   305.13 (+0.54%)
NASDAQ:IRWD

Ironwood Pharmaceuticals - IRWD Stock Forecast, Price & News

$10.44
+0.07 (+0.68%)
(As of 03/20/2023 12:00 AM ET)
Add
Compare
Today's Range
$10.36
$10.57
50-Day Range
$10.37
$11.85
52-Week Range
$9.73
$12.95
Volume
1.55 million shs
Average Volume
2.06 million shs
Market Capitalization
$1.61 billion
P/E Ratio
10.76
Dividend Yield
N/A
Price Target
$14.67

Ironwood Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
40.5% Upside
$14.67 Price Target
Short Interest
Bearish
10.72% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.94
Upright™ Environmental Score
News Sentiment
1.32mentions of Ironwood Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$2.41 M Sold Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.15 out of 5 stars

Medical Sector

400th out of 989 stocks

Pharmaceutical Preparations Industry

181st out of 483 stocks


IRWD stock logo

About Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock

Ironwood Pharmaceuticals, Inc. is a healthcare company, which engages in the development and commercialization of Gastrointestinal (GI) products. It operates through the Human Therapeutics segment. The company was founded on January 5, 1998 and is headquartered in Boston, MA.

Receive IRWD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ironwood Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

IRWD Stock News Headlines

Check Out This 6-Year Win Streak
Despite the volatility of the last few years, this reclusive millionaire hasn’t closed a losing trade since July 2016. He just plugs away, executing what may be the most effective investment strategy on Earth. He turned $50K into $5.3M! Want to see the details? Click HERE to watch it for yourself. pixel
Check Out This 6-Year Win Streak
Despite the volatility of the last few years, this reclusive millionaire hasn’t closed a losing trade since July 2016. He just plugs away, executing what may be the most effective investment strategy on Earth. He turned $50K into $5.3M! Want to see the details? Click HERE to watch it for yourself. pixel
Ironwood (IRWD) Gets FDA Priority Tag for Linzess sNDA
Ironwood Pharma: FDA Grants Priority Review To SNDA For LINZESS
15 Small Innovative Companies According to the Media
Ironwood Cuts Annual Outlook Below View; Stock Down In Pre-market
Ironwood's (IRWD) Q3 Earnings Beat, Linzess Volume Grows
See More Headlines
Receive IRWD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ironwood Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

IRWD Company Calendar

Last Earnings
2/16/2023
Today
3/20/2023
Next Earnings (Estimated)
5/04/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:IRWD
CUSIP
46333X10
Employees
219
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$14.67
High Stock Price Forecast
$16.00
Low Stock Price Forecast
$13.00
Forecasted Upside/Downside
+41.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$175.07 million
Pretax Margin
61.48%

Debt

Sales & Book Value

Annual Sales
$410.60 million
Cash Flow
$1.14 per share
Book Value
$4.24 per share

Miscellaneous

Free Float
133,963,000
Market Cap
$1.60 billion
Optionable
Optionable
Beta
0.94

Key Executives

  • Thomas A. McCourtThomas A. McCourt
    President, Chief Executive Officer & Director
  • Jason RickardJason Rickard
    Chief Operating Officer & Senior Vice President
  • Sravan Kumar Emany
    Chief Financial Officer & Senior Vice President
  • Marcel Moulaison
    Vice President-Technical Operations
  • Michael ShetzlineMichael Shetzline
    Chief Medical Officer, Senior VP, Head-R&D













IRWD Stock - Frequently Asked Questions

Should I buy or sell Ironwood Pharmaceuticals stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ironwood Pharmaceuticals in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IRWD shares.
View IRWD analyst ratings
or view top-rated stocks.

What is Ironwood Pharmaceuticals' stock price forecast for 2023?

3 Wall Street analysts have issued 12 month price targets for Ironwood Pharmaceuticals' stock. Their IRWD share price forecasts range from $13.00 to $16.00. On average, they expect the company's stock price to reach $14.67 in the next twelve months. This suggests a possible upside of 39.8% from the stock's current price.
View analysts price targets for IRWD
or view top-rated stocks among Wall Street analysts.

How have IRWD shares performed in 2023?

Ironwood Pharmaceuticals' stock was trading at $12.39 at the beginning of the year. Since then, IRWD stock has decreased by 15.3% and is now trading at $10.49.
View the best growth stocks for 2023 here
.

When is Ironwood Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our IRWD earnings forecast
.

How were Ironwood Pharmaceuticals' earnings last quarter?

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) posted its quarterly earnings results on Thursday, February, 16th. The biotechnology company reported $0.27 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.28 by $0.01. The biotechnology company earned $107.20 million during the quarter, compared to analysts' expectations of $108.23 million. Ironwood Pharmaceuticals had a trailing twelve-month return on equity of 30.49% and a net margin of 42.64%. The company's quarterly revenue was down 8.5% on a year-over-year basis. During the same period in the prior year, the business earned $0.27 EPS.

What guidance has Ironwood Pharmaceuticals issued on next quarter's earnings?

Ironwood Pharmaceuticals updated its FY 2023 earnings guidance on Tuesday, February, 28th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $420.00 million-$435.00 million, compared to the consensus revenue estimate of $426.76 million.

What is Mark Mallon's approval rating as Ironwood Pharmaceuticals' CEO?

7 employees have rated Ironwood Pharmaceuticals Chief Executive Officer Mark Mallon on Glassdoor.com. Mark Mallon has an approval rating of 93% among the company's employees. This puts Mark Mallon in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Ironwood Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ironwood Pharmaceuticals investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), NIC (EGOV), Athabasca Oil (ATH), Allergan (AGN), Aegean Marine Petroleum Network (ANW), Micron Technology (MU) and Starbucks (SBUX).

What is Ironwood Pharmaceuticals' stock symbol?

Ironwood Pharmaceuticals trades on the NASDAQ under the ticker symbol "IRWD."

Who are Ironwood Pharmaceuticals' major shareholders?

Ironwood Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include LSV Asset Management (5.17%), Renaissance Technologies LLC (2.85%), Millennium Management LLC (2.60%), Dimensional Fund Advisors LP (2.39%), Victory Capital Management Inc. (1.88%) and Geode Capital Management LLC (1.64%). Insiders that own company stock include Alexander J Denner, Andrew Davis, Jason Rickard, Julie Mchugh, Kelly Macdonald, Mark G Currie, Marla L Kessler, Michael Shetzline, Ronald Silver, Thomas A Mccourt and Timothy M O'reilly.
View institutional ownership trends
.

How do I buy shares of Ironwood Pharmaceuticals?

Shares of IRWD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ironwood Pharmaceuticals' stock price today?

One share of IRWD stock can currently be purchased for approximately $10.49.

How much money does Ironwood Pharmaceuticals make?

Ironwood Pharmaceuticals (NASDAQ:IRWD) has a market capitalization of $1.62 billion and generates $410.60 million in revenue each year. The biotechnology company earns $175.07 million in net income (profit) each year or $0.97 on an earnings per share basis.

How many employees does Ironwood Pharmaceuticals have?

The company employs 219 workers across the globe.

How can I contact Ironwood Pharmaceuticals?

Ironwood Pharmaceuticals' mailing address is 100 SUMMER STREET SUITE 2300, BOSTON MA, 02110. The official website for the company is www.ironwoodpharma.com. The biotechnology company can be reached via phone at (617) 621-7722, via email at mkaya@ironwoodpharma.com, or via fax at 617-494-0480.

This page (NASDAQ:IRWD) was last updated on 3/20/2023 by MarketBeat.com Staff